Uterine cancer clinical trials are conducted at Moffitt Cancer Center, where we continue to lead the way in researching and developing new and better treatments for all forms of cancer. At a single location, our patients have access to the latest treatment options, including promising new clinical trials, as well as advice, support and outstanding care from board-certified physicians. Any interested patient is welcome to consult with our team of experts – with or without a referral – to learn about available treatment options and find out if she is eligible to participate in a clinical trial.
We continue to lead the way in researching and developing new and better treatments and trials for uterine cancer.
Many prospective clinical trial participants are naturally concerned about safety, and often ask how a patient will be protected if she decides to take part. At Moffitt, each clinical trial is developed in accordance with a research plan, or protocol. The protocol for uterine cancer clinical trials, which is designed to protect the health, safety and well-being of participants, outlines:
Additionally, each proposed study must adhere to strict guidelines, and its compliance is continually monitored by an Institutional Review Board (IRB). An IRB is an independent ethics committee that is formally designated to review and monitor the progress of medical research to ensure that participants are continually protected.
At Moffitt, we continue to make significant progress in researching and developing new cancer treatments. In recognition of our efforts, Moffitt has been designated a Comprehensive Cancer Center by the National Cancer Institute. Through our robust clinical trial offerings, we are able to make promising experimental therapies available to patients who qualify, and our multispecialty team of uterine cancer experts ensures the best possible care for each patient.
If you’d like to discuss uterine cancer clinical trials with the team of clinical trial navigators, please call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Disease Site: Other Female Genital, Endometrial/Uterine
View Trial Details